Antonella Ravaggi
ORCID: 0000-0003-4661-9979
· 7 papers in corpus
other
2026
STUDY QUESTION: Can a serum miRNA signature serve as a potential diagnostic biomarker for endometriosis (END)? SUMMARY ANSWER: A miRNA-based diagnostic model demonstrated an accuracy of 65.8% in distinguishing END patients from control sub…
article
2025
INTRODUCTION: Endometriosis (END) is a debilitating gynecological disorder. Clinical examination, imaging, and laparoscopy can provide a definitive diagnosis of END. The discovery of non-invasive biomarkers is necessary to overcome the disa…
other
2024
BACKGROUND/OBJECTIVES: Endometriosis (END) is a painful gynecological condition. Clinical examination, imaging, and laparoscopy can provide a definitive diagnosis of END. Nonetheless, non-invasive biomarkers could help enhance and streamlin…
2017
BackgroundEpithelial ovarian cancer (EOC) is a spectrum of different diseases, which makes their treatment a challenge. Forkhead box M1 (FOXM1) is an oncogene aberrantly expressed in many solid cancers including serous EOC, but its role in …
article
2015
Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy
ObjectiveThe aim of the study was to assess the utility of serum human epididymal secretory protein E4 (HE4) biomarker in the differential diagnosis of endometriosis and adnexal malignancies.MethodsMulticentric prospective observational stu…
article
2013
BACKGROUND: Human epididymis protein 4 (HE4), kallikrein 6 (KLK6), osteopontin (OPN) and soluble mesothelin-related peptide (SMRP) are new promising biomarkers that could integrate CA125 in epithelial ovarian cancer (EOC) diagnosis. The aut…
other
2011
BACKGROUND: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC). METHODS: Preoperative serum …